Pan R, Sampson J, Chen Y, Vaine M, Wang S, Lu S
J Virol. 2013; 87(18):10221-31.
PMID: 23864637
PMC: 3754018.
DOI: 10.1128/JVI.00843-13.
Brown S, Surman S, Sealy R, Jones B, Slobod K, Branum K
Viruses. 2010; 2(2):435-467.
PMID: 20407589
PMC: 2855973.
DOI: 10.3390/v2020435.
Sealy R, Slobod K, Flynn P, Branum K, Surman S, Jones B
Int Rev Immunol. 2009; 28(1):49-68.
PMID: 19241253
PMC: 2649747.
DOI: 10.1080/08830180802495605.
Goh G, Dunker A, Uversky V
BMC Genomics. 2008; 9 Suppl 2:S4.
PMID: 18831795
PMC: 2559894.
DOI: 10.1186/1471-2164-9-S2-S4.
Pantophlet R, Wrin T, Cavacini L, Robinson J, Burton D
Virology. 2008; 381(2):251-60.
PMID: 18822440
PMC: 2613967.
DOI: 10.1016/j.virol.2008.08.032.
Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
Pantophlet R, Aguilar-Sino R, Wrin T, Cavacini L, Burton D
Virology. 2007; 364(2):441-53.
PMID: 17418361
PMC: 1985947.
DOI: 10.1016/j.virol.2007.03.007.
Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.
York J, Follis K, Trahey M, Nyambi P, Zolla-Pazner S, Nunberg J
J Virol. 2001; 75(6):2741-52.
PMID: 11222697
PMC: 115898.
DOI: 10.1128/JVI.75.6.2741-2752.2001.
Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements.
Balbach J, Yang J, Weliky D, Steinbach P, Tugarinov V, Anglister J
J Biomol NMR. 2000; 16(4):313-27.
PMID: 10826883
DOI: 10.1023/a:1008343623240.
Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
Lockey T, Slobod K, Caver T, DCosta S, Owens R, McClure H
Immunol Res. 2000; 21(1):7-21.
PMID: 10803879
DOI: 10.1385/IR:21:1:7.
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
Binley J, Sanders R, CLAS B, Schuelke N, Master A, Guo Y
J Virol. 2000; 74(2):627-43.
PMID: 10623724
PMC: 111582.
DOI: 10.1128/jvi.74.2.627-643.2000.
Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
Hoffman T, LaBranche C, Zhang W, Canziani G, Robinson J, Chaiken I
Proc Natl Acad Sci U S A. 1999; 96(11):6359-64.
PMID: 10339592
PMC: 26886.
DOI: 10.1073/pnas.96.11.6359.
The maltose-binding protein as a scaffold for monovalent display of peptides derived from phage libraries.
Zwick M, Bonnycastle L, Noren K, Venturini S, Leong E, Barbas 3rd C
Anal Biochem. 1998; 264(1):87-97.
PMID: 9784192
PMC: 3998728.
DOI: 10.1006/abio.1998.2793.
Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.
Follis K, Trahey M, LaCasse R, Nunberg J
J Virol. 1998; 72(9):7603-8.
PMID: 9696861
PMC: 110016.
DOI: 10.1128/JVI.72.9.7603-7608.1998.
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
LaCasse R, Follis K, Moudgil T, Trahey M, Binley J, Planelles V
J Virol. 1998; 72(3):2491-5.
PMID: 9499111
PMC: 109550.
DOI: 10.1128/JVI.72.3.2491-2495.1998.
Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
Smith A, Geisler S, Chen A, Resnick D, Roy B, Lewi P
J Virol. 1998; 72(1):651-9.
PMID: 9420270
PMC: 109419.
DOI: 10.1128/JVI.72.1.651-659.1998.
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
Boyd M, Gustafson K, McMahon J, Shoemaker R, OKeefe B, Mori T
Antimicrob Agents Chemother. 1997; 41(7):1521-30.
PMID: 9210678
PMC: 163952.
DOI: 10.1128/AAC.41.7.1521.
Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.
Gauduin M, Allaway G, Maddon P, Barbas 3rd C, Burton D, Koup R
J Virol. 1996; 70(4):2586-92.
PMID: 8642690
PMC: 190106.
DOI: 10.1128/JVI.70.4.2586-2592.1996.
Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.
Lombardi S, Garzelli C, La Rosa C, Zaccaro L, Specter S, Malvaldi G
J Virol. 1993; 67(8):4742-9.
PMID: 8392611
PMC: 237860.
DOI: 10.1128/JVI.67.8.4742-4749.1993.
Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.
Rini J, Stanfield R, Stura E, Salinas P, Profy A, Wilson I
Proc Natl Acad Sci U S A. 1993; 90(13):6325-9.
PMID: 8327513
PMC: 46921.
DOI: 10.1073/pnas.90.13.6325.
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
Roderiquez G, Oravecz T, BERMAN P, Lusso P, Norcross M
J Virol. 1994; 68(9):6006-13.
PMID: 8057475
PMC: 237005.
DOI: 10.1128/JVI.68.9.6006-6013.1994.